BioXcel Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$9.7M
Doctors Paid
2,768
Transactions
5,408
2024 Total
$5.2M
Payment Breakdown by Category
Research$8.5M (88.2%)
Consulting$420,398 (4.3%)
Food & Beverage$159,119 (1.6%)
Travel$91,244 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.5M | 161 | 88.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $455,983 | 184 | 4.7% |
| Consulting Fee | $420,398 | 52 | 4.3% |
| Food and Beverage | $159,119 | 4,205 | 1.6% |
| Travel and Lodging | $91,244 | 794 | 0.9% |
| Honoraria | $12,690 | 12 | 0.1% |
Payments by Type
Research
$8.5M
161 transactions
General
$1.1M
5,247 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA | $2.3M | 0 | 18 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY ANDSAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK TREATMENT PERIOD INSUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA WHO REQUIRE AT LEASTMODERATE TO FULL ASSISTANCE WITH ACTIVITIES OF DAILY LIVING | $2.0M | 0 | 16 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK TREATMENT PERIOD IN SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA WHO REQUIRE AT LEAST MODERATE TO FULL ASSISTANCE WITH ACTIVITIES OF DAILY LIVING | $1.5M | 0 | 10 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 OF AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND BIPOLAR DISORDER | $1.2M | 0 | 11 |
| A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype | $457,648 | 0 | 41 |
| A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. | $456,719 | 0 | 44 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 IN AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND BIPOLAR DISORDER | $448,946 | 0 | 4 |
| EVALUATION OF BXCL501 PLACEBO INSTRUCTIONS FOR USE AND COMPREHENSION OF TRAINING FOR CAREGIVERS AND PARTICIPANTS WITH AGITATION ASSOCIATED WITH ALZHEIMERS DEMENTIA PARTICIPATING IN STUDIES INVESTIGATING AT-HOME ADMINISTRATION | $91,092 | 0 | 3 |
| BXCL501401 | $81,795 | 0 | 14 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Cameron Quanbeck, M.d, M.D | Forensic Psychiatry | Sacramento, CA | $372.43 | $0 |
| Amal Saha, M.d, M.D | Psychiatry | Brooklyn, NY | $349.09 | $0 |
| Dr. Basit Qayyum, M.d, M.D | Rheumatology | New York, NY | $346.16 | $0 |
| Dr. Oscar Rodriguez, M.d, M.D | Psychiatry | New York, NY | $339.73 | $0 |
| Dr. Patrice Fouron, Do, DO | Psychiatry | Brooklyn, NY | $335.96 | $0 |
| Dr. Jason Hershberger, M.d, M.D | Forensic Psychiatry | Brooklyn, NY | $324.59 | $0 |
| John Fontanetta, Md, MD | Emergency Medicine | Belleville, NJ | $321.04 | $0 |
| Dr. Haroon Saeed, M.d, M.D | Psychiatry | Durham, NC | $305.91 | $0 |
| Arianna Palermini, Do, DO | Student in an Organized Health Care Education/Training Program | Las Vegas, NV | $301.93 | $0 |
| Dr. Bret Craytor, Md, MD | Pulmonary Disease | Texarkana, TX | $289.20 | $0 |
| Rifaat Elmallakh, M.d, M.D | Psychiatry | Louisville, KY | $288.71 | $0 |
| Audrey Summers, Md, MD | Psychiatry | Louisville, KY | $288.71 | $0 |
| Ronald Brenner, Md, MD | Psychiatry | Rockville Centre, NY | $280.99 | $0 |
| Dr. Louis Teitelbaum, M.d., L. F.a.p.a, M.D., L. F.A.P.A | Psychiatry | West Islip, NY | $275.43 | $0 |
| Dr. Adeel Anwar | Psychiatry | Brooklyn, NY | $268.42 | $0 |
| Majid Samad, M.d, M.D | Psychiatry | East Meadow, NY | $267.30 | $0 |
| Dr. Kathleen Brooks, Nurse Practitioner, NURSE PRACTITIONER | Registered Nurse | Brooklyn, NY | $263.17 | $0 |
| Chris Fortier, Do, DO | Psychiatry | Yakima, WA | $254.86 | $0 |
| Dr. George Karamigios, M.d, M.D | Mental Health | Cerritos, CA | $250.00 | $0 |
| Ms. Megan Regier, Pa-C, PA-C | Physician Assistant | Temple, TX | $249.40 | $0 |
| Victoria Wynne | Acute Care | Dallas, TX | $249.40 | $0 |
| Amy Weiss-Citrome, Md, MD | Physical Medicine & Rehabilitation | Pomona, NY | $249.40 | $0 |
| Dr. Anthony Wong, M.d, M.D | Emergency Medicine | Pittsburgh, PA | $246.21 | $0 |
| Nataliya Hayes | Registered Nurse | Denver, CO | $243.39 | $0 |
| Dr. Saranyan Senthelal, Md, MD | Psychiatry | Elmhurst, NY | $241.56 | $0 |
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. has made $9.7M in payments to 2,768 healthcare providers, recorded across 5,408 transactions in the CMS Open Payments database. In 2024, the company paid $5.2M. The top product by payment volume is IGALMI ($8.7M).
Payments were distributed across 98 medical specialties. The top specialty by payment amount is Psychiatry ($395,547 to 540 doctors).
Payment categories include: Food & Beverage ($159,119), Consulting ($420,398), Research ($8.5M), Travel & Lodging ($91,244).
BioXcel Therapeutics, Inc. is associated with 2 products in the CMS Open Payments database.